The Daikyo Crystal Zenith Insert Needle Syringe System - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Daikyo Crystal Zenith Insert Needle Syringe System


The Daikyo Crystal Zenith® Insert Needle Syringe System: A first-in-class, prefillable syringe solution for drug administration

Protect your drug product’s integrity with the industry’s first adhesive- and tungsten-free insert needle syringe system – the Daikyo Crystal Zenith Insert Needle Syringe System. Made from a break-resistant cyclic olefin polymer, the insert needle design minimizes potential contamination and product waste due to manufacturing and performance issues associated with traditional glass and staked-needle syringe systems.

The syringe barrel and piston are silicone-oil-free to help maximize purity and reduce risk. The piston with Daikyo Flurotec® barrier film helps minimize the effect of extractables and leachables. Flurotec barrier film also provides superior functional performance without the addition of silicone oil for lubricity. The syringe system is provided sterile and ready-to-fill in a package designed to be compatible with existing filling technologies.

The break-resistant system offers a variety of benefits that maximize value, enhance delivery and minimize risk, including:

  • Designed to maximize stability, purity and efficacy of your drug product
  • Manufactured to exacting standards in a clean room environment
  • 100% vision inspection
  • Potential to reduce protein aggregation caused by packaging materials
  • Excellent glass-like transparency
  • Suitable for high-viscosity products and those requiring low-temperature storage
  • Designed to be compatible with auto-injectors
  • Custom design and molding capabilities provide the flexibility to develop innovative new systems

 

West Pharmaceutical Services, Inc.
Email: westpharmaceuticalservices@westpharma.com
Website: www.westpharma.com

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here